CGM can capture glucose variations, guide insulin therapy optimisation and improve glucose levels and hypoglycaemia detection in individuals with insulin-treated type 2 diabetes receiving dialysis [98–100]. The gene discussed is INS; the disease is type 2 diabetes mellitus.